Cellebrite (CLBT) CMO details initial share, RSU and option holdings

Rhea-AI Filing Summary

Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee filed a Form 3 reporting his initial equity holdings in the company. He directly holds 147,933 Ordinary Shares, including restricted share units and performance share units granted in 2024, 2025 and 2026 with multi‑year vesting schedules.

He also holds stock options over 86,730 Ordinary Shares at an exercise price of $11.53 per share, expiring on May 19, 2034. Of these options, 37,950 are already vested and exercisable, with an additional 5,420 vesting on May 20, 2026 and every three months thereafter through May 20, 2028.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GEE DAVID NICHOLAS

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	147,933(1)(2)(3)(4)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options	(5)	05/19/2034	Ordinary Shares	86,730	$11.53	D

Explanation of Responses:

1. Includes 51,057 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on May 20, 2024, of which 5,673 vest on each of May 20, 2026 and every three months thereafter through May 20, 2028. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

2. Includes 7,836 Ordinary Shares that are represented by RSUs that were granted on February 11, 2025, of which 653 vest on each of May 11, 2026 and every three months thereafter through February 11, 2029.

3. Includes 22,694 Ordinary Shares that are represented by performance share units ("PSUs") that were granted on May 20, 2024, and vest based on the Issuer meeting certain total shareholder return thresholds for 60 consecutive trading days through May 20, 2028. Each PSU represents a contingent right to receive one Ordinary Share of the Issuer upon vesting and settlement.

4. Includes 66,346 Ordinary Shares that are represented by RSUs that were granted on February 10, 2026 and vest as follows: 16,594 vest on the one year anniversary of the grant date and 4,146 vest every three months thereafter through February 10, 2030.

5. Of these stock options, 37,950 are fully vested and exercisable and 5,420 vest on each of May 20, 2026 and every three months thereafter through May 20, 2028.

	/s/ David Gee	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Cellebrite (CLBT) Chief Marketing Officer David Gee report on this Form 3?

David Gee reports his initial equity holdings in Cellebrite DI Ltd. He discloses direct ownership of 147,933 Ordinary Shares plus stock options and multiple restricted and performance share unit awards that vest over several years, aligning part of his compensation with future share performance.

How many Cellebrite (CLBT) Ordinary Shares does David Gee beneficially own?

David Gee reports beneficial ownership of 147,933 Ordinary Shares. This total includes time‑based restricted share units and performance share units granted in 2024, 2025 and 2026, which deliver one Ordinary Share each upon vesting and settlement if their respective conditions are met.

What stock options in Cellebrite (CLBT) does David Gee hold and on what terms?

He holds stock options over 86,730 Ordinary Shares at an exercise price of $11.53 per share, expiring May 19, 2034. Of these, 37,950 options are fully vested, while 5,420 additional options vest on May 20, 2026 and quarterly thereafter through May 20, 2028.

What are the key restricted share unit (RSU) grants reported by Cellebrite (CLBT) CMO David Gee?

His holdings include 51,057 RSU‑based shares granted May 20, 2024 and 7,836 RSU‑based shares granted February 11, 2025. These RSUs vest in equal quarterly installments beginning May 20, 2026 and May 11, 2026, respectively, continuing through 2028 and 2029 as described.

What performance share units (PSUs) in Cellebrite (CLBT) are included in David Gee’s holdings?

His position includes 22,694 Ordinary Shares represented by PSUs granted May 20, 2024. These PSUs vest only if Cellebrite meets specified total shareholder return thresholds for 60 consecutive trading days through May 20, 2028, after which each PSU converts into one Ordinary Share upon settlement.

What additional RSU grant did Cellebrite (CLBT) make to David Gee in 2026?

He reports 66,346 Ordinary Shares represented by RSUs granted February 10, 2026. For this award, 16,594 RSU‑based shares vest on the one‑year anniversary of the grant, with 4,146 additional shares vesting every three months through February 10, 2030, subject to continued service.